GlassScriptPhysician profile
John H Powell
NPI 1194725432
$4,527.60
in general payments reported to CMS, 2019-2025
52 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.49 · 2022: $392 · 2023: $2,134 · 2024: $1,507 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,045 · Education: $41.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,044.84 |
| Education | $41.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $460.37 | 2022-2025 | Keytruda, Reblozyl, Lynparza |
| Astrazeneca Pharmaceuticals LP | $336.14 | 2023-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $322.01 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $266.20 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $265.14 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $251.20 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $249.34 | 2021-2024 | |
| Abbvie INC. | $198.86 | 2023-2025 | |
| Eisai INC. | $192.33 | 2023-2025 | |
| Daiichi Sankyo INC. | $148.02 | 2023-2025 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $140.67 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Exelixis INC. | $108.94 | 2023-2024 | Cabometyx |
| Pfizer INC. | $108.57 | 2023-2024 | |
| Taiho Oncology, INC. | $98.93 | 2023-2024 | |
| Amgen INC. | $92.59 | 2021-2023 | Xgeva, Vectibix, Nplate |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $87.13 | 2023-2024 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $85.18 | 2022-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $74.55 | 2023-2024 | Reblozyl, Pomalyst |
| Seagen INC. | $74.08 | 2023 | Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $69.38 | 2023-2024 | Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $69.09 | 2023-2024 | Opdualag, Opdivo |
| Blueprint Medicines Corporation | $65.39 | 2023-2024 | Ayvakit |
| Genentech USA, INC. | $59.60 | 2023-2024 | Perjeta, Phesgo, Tecentriq |
| Genzyme Corporation | $50.14 | 2022-2023 | |
| Tersera Therapeutics LLC | $49.73 | 2023-2024 | Zoladex |
| Sobi, INC | $40.42 | 2023 | |
| Mirati Therapeutics, INC. | $37.46 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $36.66 | 2024 | |
| Morphosys, US INC. | $35.44 | 2023-2024 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $32.49 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $31.76 | 2022-2023 | Libtayo |
| Janssen Pharmaceuticals, INC | $30.79 | 2023 | Xarelto |
| Springworks Therapeutics, INC. | $26.63 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $22.20 | 2024 | |
| Kyowa Kirin, INC. | $21.41 | 2024 | Poteligeo |
| Genmab U.S., INC. | $21.25 | 2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $21.03 | 2025 | Clonoseq |
| Corcept Therapeutics | $20.46 | 2025 | Korlym |
| Array Biopharma INC | $18.84 | 2025 | Mektovi, Braftovi, Lorbrena |
| Syndax Pharmaceuticals, INC. | $18.51 | 2025 | |
| Karyopharm Therapeutics INC. | $17.72 | 2024 | Xpovio |
| Apellis Pharmaceuticals, INC. | $17.38 | 2024 | Empaveli |
| Puma Biotechnology, INC. | $17.13 | 2023 | |
| Sun Pharmaceutical Industries INC. | $16.95 | 2023 | Odomzo, Yonsa |
| Pharmacosmos Therapeutics INC. | $16.48 | 2024 | Cosela |
| Incyte Corporation | $16.20 | 2023 | Monjuvi, Zynyz, Pemazyre |
| Pharmaessentia USA Corporation | $15.81 | 2024 | Besremi |
| Kite Pharma, INC. | $15.48 | 2024 | Yescarta |
| Beigene USA, INC. | $15.47 | 2023 | Brukinsa |
| Foundation Medicine, INC. | $14.36 | 2023 | |
| Geron Corporation | $13.67 | 2025 | Rytelo |
| Coherus Oncology, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.